| Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non–small cell lung cancer with use of a next-generation sequencing … Z Wang, J Duan, S Cai, M Han, H Dong, J Zhao, B Zhu, S Wang, M Zhuo, ... JAMA oncology 5 (5), 696-702, 2019 | 432 | 2019 |
| TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer J Han, J Duan, H Bai, Y Wang, R Wan, X Wang, S Chen, Y Tian, D Wang, ... Cancer immunology research 8 (1), 146-154, 2020 | 207 | 2020 |
| Multiregion sequencing reveals the genetic heterogeneity and evolutionary history of osteosarcoma and matched pulmonary metastases D Wang, X Niu, Z Wang, CL Song, Z Huang, KN Chen, J Duan, H Bai, ... Cancer research 79 (1), 7-20, 2019 | 121 | 2019 |
| Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L) 1 Inhibitors Z Wang, J Duan, G Wang, J Zhao, J Xu, J Han, Z Zhao, J Zhao, B Zhu, ... Journal of Thoracic Oncology 15 (4), 556-567, 2020 | 72 | 2020 |
| Prediction of chemotherapeutic efficacy in non–small cell lung cancer by serum metabolomic profiling Y Tian, Z Wang, X Liu, J Duan, G Feng, Y Yin, J Gu, Z Chen, S Gao, H Bai, ... Clinical Cancer Research 24 (9), 2100-2109, 2018 | 57 | 2018 |
| Anaplastic lymphoma kinase variants and the percentage of ALK-positive tumor cells and the efficacy of crizotinib in advanced NSCLC YY Lei, JJ Yang, XC Zhang, WZ Zhong, Q Zhou, HY Tu, HX Tian, WB Guo, ... Clinical Lung Cancer 17 (3), 223-231, 2016 | 56 | 2016 |
| Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma X He, Y Du, Z Wang, X Wang, J Duan, R Wan, J Xu, P Zhang, D Wang, ... Journal for ImmunoTherapy of Cancer 8 (2), 2020 | 36 | 2020 |
| Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer L Cai, H Bai, J Duan, Z Wang, S Gao, D Wang, S Wang, J Jiang, J Han, ... Journal for Immunotherapy of Cancer 7, 1-11, 2019 | 34 | 2019 |
| Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases YY Lei, JJ Yang, WZ Zhong, HJ Chen, HH Yan, JF Han, LL Yang, YL Wu Journal of thoracic disease 7 (7), 1181, 2015 | 21 | 2015 |
| Refined stratification based on baseline concomitant mutations and longitudinal circulating tumor DNA monitoring in advanced EGFR-mutant lung adenocarcinoma under gefitinib … J Duan, JC Xu, Z Wang, H Bai, Y Cheng, T An, H Gao, K Wang, Q Zhou, ... Journal of Thoracic Oncology 15 (12), 1857-1870, 2020 | 20 | 2020 |
| Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer A Li, FY Niu, JF Han, NN Lou, JJ Yang, XC Zhang, Q Zhou, Z Xie, J Su, ... Lung Cancer 90 (3), 375-380, 2015 | 20 | 2015 |
| TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib R Yu, H Bai, T Li, B Gao, J Han, G Chang, P Zhang, K Fei, X He, J Wang Translational Oncology 14 (9), 101163, 2021 | 18 | 2021 |
| The BCL11A-XL expression predicts relapse in squamous cell carcinoma and large cell carcinoma N Zhang, BY Jiang, XC Zhang, Z Xie, J Su, Q Zhang, JF Han, HY Tu, ... Journal of thoracic disease 7 (9), 1630, 2015 | 17 | 2015 |
| Soluble c-Met Levels Correlated With Tissue c-Met Protein Expression in Patients With Advanced Non–Small-Cell Lung Cancer HF Gao, AN Li, JJ Yang, ZH Chen, Z Xie, XC Zhang, J Su, NN Lou, ... Clinical Lung Cancer 18 (1), 85-91, 2017 | 16 | 2017 |
| Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non–small cell lung cancers J Han, R Yu, J Duan, J Li, W Zhao, G Feng, H Bai, Y Wang, X Zhang, ... Science Advances 7 (21), eabd6971, 2021 | 13 | 2021 |
| Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer Y Zuo, J Zhong, H Bai, B Xu, Z Wang, W Li, Y Chen, S Jin, S Wang, ... EBioMedicine 82, 2022 | 9 | 2022 |
| Polymorphism of rs9387478 correlates with overall survival in female nonsmoking patients with lung cancer JF Han, SJ An, WM Su, ZH Chen, J Su, H Yan, WB Guo, SL Chen, ... The International Journal of Biological Markers 31 (2), 144-152, 2016 | 4 | 2016 |
| A novel noninvasive biomarker based on peripheral PD-1posi CD8 T-cell receptor repertoire correlated with clinical outcomes to immunotherapy in non-small cell … JF Han, Z Wang, H Bai, S Chen, Y Wang, J Duan, J Wang Journal of Clinical Oncology 37 (15_suppl), e14174-e14174, 2019 | 2 | 2019 |
| Dynamic clonality of T cell receptor differentiate atypical progression in NSCLC patients treated with PD-1/PD-L1inhibitors J Han, Z Wang, Y Wang, S Chen, H Bai, J Duan, J Wang Cancer Research 79 (13_Supplement), 3247-3247, 2019 | 1 | 2019 |
| JCES01. 24 Molecular Mechanism of Transformation from Adenocarcinoma to Small-Cell Lung Cancer after EGFR-TKI J Han, Q Zhang, B Wang, Q Zhou, L Yan, Z Zhang, H Chen, J Su, Z Xie, ... Journal of Thoracic Oncology 12 (1), S240-S241, 2017 | 1 | 2017 |
